A phase i trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 967-973

  Naing, Aung ^a   Cohen, Roger ^b   Dy, Grace K ^c   Hong, David S ^a   Dyster, Lyn ^d   Hangauer, David G ^d   Kwan, Rudolf ^d   Fetterly, Gerald ^c   Kurzrock, Razelle ^e   Adjei, Alex A ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Kinex Pharmaceuticals   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

KX2 391; Ovarian; Phase I; Prostate; Src kinase

Indexed keywords

CA 19-9 ANTIGEN; KX 2 391; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOID; CARDIOTOXICITY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; EDEMA; FAILURE TO THRIVE; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERTRANSAMINASEMIA; HYPONATREMIA; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; STEADY STATE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THYROID CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ACETAMIDES; ADENOSINE TRIPHOSPHATE; BINDING SITES; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; SRC-FAMILY KINASES; SUBSTRATE SPECIFICITY;

EID: 84880919122     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9929-8     Document Type: Article

References (13)

1. Summy JM, Gallick GE (2003) SRC family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337-358
2. Puls LN, Eadens M, Messersmith W (2011) Current status of SRC inhibitors in solid tumor malignancies. Oncologist 16(5):566-578
3. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG (2012) Kx-01, a novel SRC kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Breast Canc Res Treat 132(2):391-409
4. Fallah-Tafti A, Foroumadi A, Tiwari R, Shirazi AN, Hangauer DG, Bu Y, Akbarzadeh T, Parang K, Shafiee A (2011) Thiazolyl n-benzyl-substituted acetamide derivatives: synthesis, SRC kinase inhibitory and anticancer activities. Eur J Med Chem 46(10):4853-4858
5. Lau GM, Yu GL, Gelman IH, Gutowski A, Hangauer D, Fang JW (2009) Expression of SRC and FAK in hepatocellular carcinoma and the effect of SRC inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci 54(7):1465-1474
6. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P (1999) Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Canc Inst 91(6):523-528
7. Zarbock A (2012) The shady side of dasatinib. Blood 119(21):4817-4818
8. Mould T (2012) An overview of current diagnosis and treatment in ovarian cancer. Int J Gynecol Canc Official J I Gynecol Canc Soc 22(Suppl 1):S2-S4
9. Yared JA, Tkaczuk KH (2012) Update on taxane development: new analogs and new formulations. Drug Des Dev Ther 6:371-384
10. Leung EL, Wong JC, Johlfs MG, Tsang BK, Fiscus RR (2010) Protein kinase g type ialpha activity in human ovarian cancer cells significantly contributes to enhanced src activation and DNA synthesis/cell proliferation. Mol Canc Res MCR 8(4):578-591
11. Le XF, Bast RC Jr (2011) SRC family kinases and paclitaxel sensitivity. Canc Biol Ther 12(4):260-269
12. Cai H, Babic I, Wei X, Huang J, Witte ON (2011) Invasive prostate carcinoma driven by c-SRC and androgen receptor synergy. Cancer Res 71(3):862-872
13. Rice L, Lepler S, Pampo C, Siemann DW (2012) Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin Exp Metastasis 29(2):133-142